A €15 million Series A fundraising round was secured by Vienna, Austria-based Ygion Biomedical, a business focused on creating personalized cancer vaccines based on neoantigens.
Among the supporters was an unidentified private investor from Austria.
Use of funds
The funds will be used by the business to progress the principal program YG-01 into preclinical and clinical development, as well as to further develop its YGNITETM technology platform.
YG-01, the flagship initiative of YGION, is now undergoing preclinical testing.
About Ygion Biomedical
Ygion Biomedical is focused on developing customized “plug-and-play” cancer vaccines using a proprietary suite of technologies to locate, create, and target the delivery of pertinent peptide neoepitopes that precisely and precisely activate the patient’s immune system. The company is led by CEO Dr. Wolfgang Fischl and Chief Technology Officer Dr. Geert Mudde. Neoepitope peptide vaccines customized for each tumor and patient are delivered via its YGNITETM technology, which integrates sequencing, analytics, and the exclusive CARGONAUTTM vaccine platform.
